Safety of intravenous thrombolysis for acute ischemic stroke in specific conditions

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F15%3A00064391" target="_blank" >RIV/00159816:_____/15:00064391 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1517/14740338.2015.1032242" target="_blank" >http://dx.doi.org/10.1517/14740338.2015.1032242</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1517/14740338.2015.1032242" target="_blank" >10.1517/14740338.2015.1032242</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Safety of intravenous thrombolysis for acute ischemic stroke in specific conditions

Popis výsledku v původním jazyce

Introduction: Intravenous administration of tissue-type plasminogen activator (IV-tPA) remains the only approved therapy that may reverse neurological deficit in patients with acute ischemic stroke (AIS). During the past 20 years, accumulating real-wordexperience have provided additional information regarding its safety and efficacy in various clinical settings that were originally considered as contraindications for systemic thrombolysis. Areas covered: In this narrative review, we address the safetyof intravenous thrombolysis (IVT) in specific conditions: dissection of the aortic arch of extracranial and intracranial arteries, concomitant presence of unruptured intracranial aneurysms, arteriovenous malformations and dural fistulas, coexisting braintumors as well as in conditions mimicking AIS. The review systematically evaluates the safety of off-label use of IVT and summarizes data from case reports of uncommon complications of systemic thrombolysis administration in the setting

Název v anglickém jazyce

Safety of intravenous thrombolysis for acute ischemic stroke in specific conditions

Popis výsledku anglicky

Introduction: Intravenous administration of tissue-type plasminogen activator (IV-tPA) remains the only approved therapy that may reverse neurological deficit in patients with acute ischemic stroke (AIS). During the past 20 years, accumulating real-wordexperience have provided additional information regarding its safety and efficacy in various clinical settings that were originally considered as contraindications for systemic thrombolysis. Areas covered: In this narrative review, we address the safetyof intravenous thrombolysis (IVT) in specific conditions: dissection of the aortic arch of extracranial and intracranial arteries, concomitant presence of unruptured intracranial aneurysms, arteriovenous malformations and dural fistulas, coexisting braintumors as well as in conditions mimicking AIS. The review systematically evaluates the safety of off-label use of IVT and summarizes data from case reports of uncommon complications of systemic thrombolysis administration in the setting

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FR - Farmakologie a lékárnická chemie

OECD FORD obor

—

Projekt

<a href="/cs/project/ED1.100%2F02%2F0123" target="_blank" >ED1.100/02/0123: Fakultní nemocnice u sv. Anny v Brně - Mezinárodní centrum klinického výzkumu (FNUSA - ICRC)</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Expert Opinion On Drug Safety

ISSN

1474-0338

e-ISSN

—

Svazek periodika

14

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

20

Strana od-do

845-864

Kód UT WoS článku

000354541400006

EID výsledku v databázi Scopus

—